Abituzumab
As of the edition of 20 October 2026, Abituzumab is an antibody: stopped in 2021; acts on ITGAV.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Antibody
- Registered trials
- 7, 2 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Skin and connective tissue; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Abituzumab.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ITGAV | Integrin alpha-V | P06756 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 4 | 2 | 0 | 2 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck KGaA | Lead sponsor of trials | 2008 to now |
| SFJ Pharmaceuticals X | Lead sponsor of trials | 2019 to now |